{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT02218437",
      "OrgStudyIdInfo": {
        "OrgStudyId": "MSC-2014-SAA-1"
      },
      "SecondaryIdInfoList": {
        "SecondaryIdInfo": [
          {
            "SecondaryId": "H0806-MSC-2014",
            "SecondaryIdType": "Other Grant/Funding Number",
            "SecondaryIdDomain": "NSFC"
          }
        ]
      },
      "Organization": {
        "OrgFullName": "Chinese Academy of Medical Sciences",
        "OrgClass": "OTHER"
      },
      "BriefTitle": "Treatment Protocol of Child SAA With the Injection of Mesenchymal Stem Cells（Umbilical Cord Derived）",
      "OfficialTitle": "Child With Severe Aplastic Anemia (SAA) Therapy: the Injection of Umbilical Cord Derived Mesenchymal Stem Cells.",
      "Acronym": "MSC-SAA"
    },
    "StatusModule": {
      "StatusVerifiedDate": "August 2014",
      "OverallStatus": "Unknown status",
      "LastKnownStatus": "Recruiting",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "October 2013"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "October 2015",
        "PrimaryCompletionDateType": "Anticipated"
      },
      "CompletionDateStruct": {
        "CompletionDate": "October 2015",
        "CompletionDateType": "Anticipated"
      },
      "StudyFirstSubmitDate": "August 6, 2014",
      "StudyFirstSubmitQCDate": "August 14, 2014",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "August 18, 2014",
        "StudyFirstPostDateType": "Estimate"
      },
      "LastUpdateSubmitDate": "August 14, 2014",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "August 18, 2014",
        "LastUpdatePostDateType": "Estimate"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyType": "Principal Investigator",
        "ResponsiblePartyInvestigatorFullName": "Xiaofan Zhu",
        "ResponsiblePartyInvestigatorTitle": "chief physician",
        "ResponsiblePartyInvestigatorAffiliation": "Chinese Academy of Medical Sciences"
      },
      "LeadSponsor": {
        "LeadSponsorName": "Chinese Academy of Medical Sciences",
        "LeadSponsorClass": "OTHER"
      }
    },
    "OversightModule": {
      "OversightHasDMC": "Yes"
    },
    "DescriptionModule": {
      "BriefSummary": "Mesenchymal Stem Cells (MSC) is a non Hematopoietic Stem Cells (HSC) in adult bone marrow and takes part in the bone marrow microenvironment. The response rate of early treatment on Children's SAA application combined with anti-thymocyte globulin (ATG) (40-50 days after ATG treatment) is associated with long-term effect. The injection of Umbilical Cord Derived Mesenchymal Stem Cells combined with ATG improves the efficacy of children with SAA.",
      "DetailedDescription": "Mesenchymal Stem Cells were prepared by in vitro separation, screening, and culture from healthy human umbilical cord tissue; The \" injection of mesenchymal stem cells (umbilical) manufacturing and verification regulation \" was also formulated.\nThe starting dose of Umbilical Cord Derived MSC was 0.5-1.0 * 106 cells /kg, based on the previous human studies; And the maximum tolerated dose was 1 * 107 cells /kg\nThe response and complete remission rate, relapse rate of the injection of Umbilical Cord Derived Mesenchymal Stem Cells (or combined with ATG ) for Child with SAA were determined."
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Complications of Organ Transplant Stem Cells Umbilical Cord"
        ]
      },
      "KeywordList": {
        "Keyword": [
          "Mesenchymal Stem Cells (MSC)",
          "Umbilical Cord",
          "thymocyte globulin (ATG)",
          "Severe Aplastic Anemia (SAA)"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Phase 4"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "N/A",
        "DesignInterventionModel": "Single Group Assignment",
        "DesignPrimaryPurpose": "Treatment",
        "DesignMaskingInfo": {
          "DesignMasking": "None (Open Label)"
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "20",
        "EnrollmentType": "Anticipated"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "MSC+ATG",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "The first agent MSC injection, began two weeks after ATG application; Each patient was injected three times, one time per week; Study on single dose tolerance and efficacy index; Each subjects received three dose groups of treatment.",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Drug: MSC+ATG"
              ]
            }
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Drug",
            "InterventionName": "MSC+ATG",
            "InterventionDescription": "MSC+ATG:Starting dose was 0.5-1.0 × 106 cells /kg; And the maximum tolerated dose was 1 ×107 cells /kg after ATG application.",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "MSC+ATG"
              ]
            },
            "InterventionOtherNameList": {
              "InterventionOtherName": [
                "Mesenchymal Stem Cells (Umbilical Cord Derived)"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "The response and complete remission rate with different doses of Umbilical Cord Derived MSC to treat child with SAA",
            "PrimaryOutcomeDescription": "Complete response (CR) was defined as achieving normal levels of hemoglobin adjusted for age, platelet count >100*109/L, and absolute neutrophil count (ANC) >1.5*1.0 9/L. Partial response (PR) was defined as injection independence, reticulocyte count>30*109/L, platelet count >20*109/L, and ANC>0.5*1.0 9/L above the baseline. Persistence of injection requirement or death was evidence of no response (NR).",
            "PrimaryOutcomeTimeFrame": "1 year"
          }
        ]
      },
      "SecondaryOutcomeList": {
        "SecondaryOutcome": [
          {
            "SecondaryOutcomeMeasure": "The relapse rate with different doses of MSC to treat child with SAA",
            "SecondaryOutcomeDescription": "The relapse was defined as injection dependence again; or progressed or paroxysmal nocturnal hemoglobinuria (PNH)/acute myeloid leukemia/myelodysplasia syndrome(MDS); or cyclosporin A (CsA) dependence.",
            "SecondaryOutcomeTimeFrame": "3-10 year"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Inclusion Criteria:\n\nNon-Severe Aplastic Anemia (NSAA)atients\n\nExclusion Criteria:\n\nSevere Aplastic Anemia (SAA) patients",
      "HealthyVolunteers": "Accepts Healthy Volunteers",
      "Gender": "All",
      "MinimumAge": "1 Month",
      "MaximumAge": "18 Years",
      "StdAgeList": {
        "StdAge": [
          "Child",
          "Adult"
        ]
      }
    },
    "ContactsLocationsModule": {
      "CentralContactList": {
        "CentralContact": [
          {
            "CentralContactName": "Xiaofan Zhu, MD",
            "CentralContactRole": "Contact",
            "CentralContactPhone": "+86-22-23909001",
            "CentralContactEMail": "zhuxf6465@gmail.com"
          }
        ]
      },
      "OverallOfficialList": {
        "OverallOfficial": [
          {
            "OverallOfficialName": "Xiaofan Zhu, MD",
            "OverallOfficialAffiliation": "Chinese Academy of Medical Sciences",
            "OverallOfficialRole": "Principal Investigator"
          }
        ]
      },
      "LocationList": {
        "Location": [
          {
            "LocationFacility": "Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences and Peking Union Medical College",
            "LocationStatus": "Recruiting",
            "LocationCity": "Tianjin",
            "LocationZip": "300020",
            "LocationCountry": "China",
            "LocationContactList": {
              "LocationContact": [
                {
                  "LocationContactName": "Xiaofan Zhu, MD",
                  "LocationContactRole": "Contact",
                  "LocationContactPhone": "+86-22-23909001",
                  "LocationContactEMail": "zhuxf6465@gmail.com"
                },
                {
                  "LocationContactName": "Xiaofan Zhu, MD",
                  "LocationContactRole": "Principal Investigator"
                }
              ]
            }
          }
        ]
      }
    },
    "ReferencesModule": {
      "ReferenceList": {
        "Reference": [
          {
            "ReferencePMID": "33639900",
            "ReferenceType": "derived",
            "ReferenceCitation": "Lan Y, Liu F, Chang L, Liu L, Zhang Y, Yi M, Cai Y, Feng J, Han Z, Han Z, Zhu X. Combination of umbilical cord mesenchymal stem cells and standard immunosuppressive regimen for pediatric patients with severe aplastic anemia. BMC Pediatr. 2021 Feb 27;21(1):102. doi: 10.1186/s12887-021-02562-x."
          }
        ]
      }
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 20, 2022"
    },
    "ConditionBrowseModule": {
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M3222",
            "ConditionBrowseLeafName": "Anemia",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M3223",
            "ConditionBrowseLeafName": "Anemia, Aplastic",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "T460",
            "ConditionBrowseLeafName": "Aplastic Anemia",
            "ConditionBrowseLeafAsFound": "Aplastic Anemia",
            "ConditionBrowseLeafRelevance": "high"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BC15",
            "ConditionBrowseBranchName": "Blood and Lymph Conditions"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          },
          {
            "ConditionBrowseBranchAbbrev": "Rare",
            "ConditionBrowseBranchName": "Rare Diseases"
          }
        ]
      }
    }
  }
}